Struggling US biotech Peptimmune seeks Chapter 7 liquidation
This article was originally published in Scrip
Executive Summary
Peptimmune, a privately held US clinical stage biotechnology company, recently filed under Chapter 7 of the bankruptcy code, according to documents filed in US Bankruptcy Court for Boston, Massachusetts. A Chapter 7 filing usually leads to liquidation. The company, founded in 2002, had focused on peptide and peptide-copolymer therapeutics for the treatment of CNS and autoimmune disorders.